Asthma Biotech Generate Biomedicines Eyes $400M IPO
By Jade Martinez-Pogue · February 23, 2026, 4:55 PM EST
Asthma-focused biotech firm Generate Biomedicines on Monday filed plans with U.S. regulators to raise around $400 million in its initial public offering led by Goodwin Procter LLP and Latham & Watkins...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login